Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia – Case Report
Ibrahim Zoubi,1 Amir Warwar,1,2 Shoshan Perek,1 Meir Preis1,2 1Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; 2Bruce and Ruth Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, IsraelCorrespondence: Meir Preis, Institute of Hematology, Lady Dav...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | ImmunoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/daratumumab-and-romiplostim-combined-therapy-for-a-long-standing-refra-peer-reviewed-fulltext-article-ITT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Ibrahim Zoubi,1 Amir Warwar,1,2 Shoshan Perek,1 Meir Preis1,2 1Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; 2Bruce and Ruth Rappaport Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, IsraelCorrespondence: Meir Preis, Institute of Hematology, Lady Davis Carmel Medical Center, 7 Michal St, Haifa, Israel, Tel +972-4-8250445, Email Meirpr@clalit.org.ilAbstract: Multi-refractory immune thrombocytopenia (ITP) is not uncommon and associated with high morbidity and mortality rates. Although the precise mechanism of ITP is not yet fully understood, a therapeutic approach that relies on using a single agent in each treatment line may not be sufficient in this population. We report the case of a 67-year-old female with long-standing multi-refractory ITP treated with a combination of Daratumumab and Romiplostim who achieved a durable response for more than 42 weeks. Owing to the presentation of chronic and refractory disease, we used a dual-agent approach to address early immune destruction and promote megakaryocyte platelet production. Three doses of Daratumumab were administered during the induction phase (weeks 0,1,5) and then at less frequent intervals - every 4– 12 weeks for total of 4 doses during the maintenance phase. Romiplostim was administered weekly, with dose modification depending on the platelet count. We hypothesize that when combined with thrombopoietin receptor agonists (TPO-RAs), daratumumab administered at less frequent intervals over an extended period can be safely used, resulting in a prolonged response.Keywords: multi-refractory immune thrombocytopenia, anti CD38 directed therapy, TPO mimetic agents, case report |
|---|---|
| ISSN: | 2253-1556 |